Location History:
- New Haven, CT (US) (2013)
- Innsbruck, AT (2019 - 2023)
Company Filing History:
3 out of 1,327 
3 out of 1,536 
1 out of 4 Years Active: 2013-2025
Title: Guido Wollmann: Innovator in Oncolytic Virus Research
Introduction
Guido Wollmann is a prominent inventor based in Innsbruck, Austria. He has made significant contributions to the field of oncolytic viruses, particularly through his innovative patents. With a total of 6 patents, Wollmann's work focuses on the development of recombinant rhabdoviruses for cancer treatment.
Latest Patents
Wollmann's latest patents include groundbreaking inventions in the realm of oncolytic viruses. One of his notable patents is for a recombinant rhabdovirus encoding for CCL21. This invention relates to the use of a recombinant rhabdovirus, such as vesicular stomatitis virus, which encodes for a CCL21 protein. The patent outlines methods for producing such viruses and their application in cancer treatment. Another significant patent involves a recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein. Similar to the previous invention, this patent also focuses on the use of the recombinant virus in cancer therapy and methods for its production.
Career Highlights
Throughout his career, Wollmann has worked with esteemed institutions, including Yale University and Boehringer Ingelheim International GmbH. His experience in these organizations has contributed to his expertise in the field of oncolytic viruses and has facilitated his innovative research.
Collaborations
Wollmann has collaborated with notable colleagues, including Anthony N Van Den Pol and Philipp Mueller. These collaborations have further enriched his research and development efforts in the field of cancer treatment.
Conclusion
Guido Wollmann is a distinguished inventor whose work in oncolytic viruses has the potential to revolutionize cancer treatment. His innovative patents and collaborations highlight his commitment to advancing medical science.